The effects of hyperprolactinemia and its control on metabolic diseases

References

• Knudtzon J, Johansen PW, Haug E, et al. Effects of hypersecretion of growth hormone and prolactin on plasma levels of glucagon and insulin in GH3-cell-tumor-bearing rats, and the influence of bromocriptine treatment. Life Sci. 1986;39:617–621.
   PubMed Web of Science ®Google Scholar
• Byatt JC, Staten NR, Salsgiver WJ, et al. Stimulation of food intake and weight gain in mature female rats by bovine prolactin and bovine growth hormone. Am J Physiol. 1993;264:E986–E992.
   PubMedGoogle Scholar
• Bole-Feysot C, Goffin V, Edery M, et al. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev. 1998;19:225–268.
   PubMed Web of Science ®Google Scholar
• Ben-Jonathan N, Hugo ER, Brandebourg TD, et al. Focus on prolactin as a metabolic hormone. Trends EndocrinolMetab. 2006;17:110–116.
   PubMed Web of Science ®Google Scholar
• Baptista T, Lacruz A, De Mendoza S, et al. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry. 2000;33:81–88.
   PubMed Web of Science ®Google Scholar
• Doknic M, Pekic S, Zarkovic M, et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol. 2002;147:77–84.
   PubMed Web of Science ®Google Scholar
• Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. ClinEndocrinol (Oxf). 1998;48:547–553.
   PubMed Web of Science ®Google Scholar
• Colao A, Sarno A, Cappabianca P, et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003;148(3):325–331.
   PubMed Web of Science ®Google Scholar
• Brandebourg T, Hugo E, Ben-Jonathan N. Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes Metab. 2007;9(4):464–476.
   PubMed Web of Science ®Google Scholar
• Strader AD, Buntin JD. Changes in agouti-related peptide during the ring dove breeding cycle in relation to prolactin and parental hyperphagia. J Neuroendocrinol. 2003;15:1046–1053.
   PubMed Web of Science ®Google Scholar
• Bina KG, Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology. 2000;71:68–78.
   PubMed Web of Science ®Google Scholar
• Atmaca A, Bilgici B, Ecemis GC, et al. Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia. Endocrine. 2013;44(3):756–761.
   PubMed Web of Science ®Google Scholar
• Highman TJ, Friedman JE, Huston LP, et al. Longitudinal changes in maternal serum leptin concentrations, body composition, and resting metabolic rate in pregnancy. Am J Obstet Gynecol. 1998;178(5):1010–1015.
   PubMed Web of Science ®Google Scholar
• Butte NF, Hopkinson JM, Nicolson MA. Leptin in human reproduction: serum leptin levels in pregnant and lactating women. J Clin Endocrinol Metab. 1997;82(2):585–589.
   PubMed Web of Science ®Google Scholar
• Balci H, Akgun-Dar K, Gazioglu N, et al. The relationship between prolactin (PRL), leptin, nitric oxide (NO), and cytokines in patients with hyperprolactinemia. Pituitary. 2009;12(3):170–176.
   PubMed Web of Science ®Google Scholar
• Augustine RA, Grattan DR. Induction of central leptin resistance in hyperphagicpseudopregnant rats by chronic prolactin infusion. Endocrinology. 2008;149:1049–1055.
   PubMed Web of Science ®Google Scholar
• Sauvé D, Woodside B. Neuroanatomical specificity of prolactin-induced hyperphagia in virgin female rats. Brain Res. 2000;868(2):306–314.
   PubMed Web of Science ®Google Scholar
• Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. Lancet. 2001;357(9253):354–357.
   PubMed Web of Science ®Google Scholar
• Kok P, Roelfsema F, Frolich M, et al. Prolactin release is enhanced in proportion to excess visceral fat in obese women. J Clin Endocrinol Metab. 2004;89:4445–4449.
   PubMed Web of Science ®Google Scholar
• Sorenson RL, Brelje TC. Adaptation of islets of Langerhans to pregnancy: β-cell growth, enhanced insulin secretion and the role of lactogenic hormones. Horm Metab Res. 1997;29:301–307.
   PubMed Web of Science ®Google Scholar
• Weinhaus AJ, Stout LE, Bhagroo NV, et al. Regulation of glucokinase in pancreatic islets by prolactin: a mechanism for increasing glucose-stimulated insulin secretion during pregnancy. J Endocrinol. 2007;193:367–381.
   PubMed Web of Science ®Google Scholar
• Nagano M, Kelly PA. Tissue distribution and regulation of rat prolactin receptor gene expression. Quantitative analysis by polymerase chain reaction. J Biol Chem. 1994;269:13337–13345.
   PubMed Web of Science ®Google Scholar
• Moldrup A, Ed P, Nielsen JH. Effects of sex and pregnancy hormones on growth hormone and prolactin receptor gene expression in insulin-producing cells. Endocrinology. 1993;133:1165–1172.
   PubMed Web of Science ®Google Scholar
• Brelje TC, Stout LE, Bhagroo NV, et al. Distinctive roles for prolactin and growth hormone in the activation of signal transducer and activator of transcription 5 in pancreatic islets of Langerhans. Endocrinology. 2004;145:4162–4175.
   PubMed Web of Science ®Google Scholar
• Vasavada RC, Garcia-Ocana A, Zawalich WS, et al. Targeted expression of placental lactogen in the β cells of transgenic mice results in β cell proliferation, islet mass augmentation, and hypoglycemia. J Biol Chem. 2000;275:15399–15406.
   PubMed Web of Science ®Google Scholar
• Landgraf R, Landraf-Leurs MM, Weissmann A, et al. Prolactin: a diabetogenic hormone. Diabetologia. 1977;13:99–104.
   PubMed Web of Science ®Google Scholar
• Johnston DG, Alberti KG, Nattrass M, et al. Hyperinsulinaemia in hyperprolactinaemic women. Clin Endocrinol (Oxf). 1980;13:361–368.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Prager R, Punzengruber C, et al. Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia. 1985;28:138–142.
   PubMed Web of Science ®Google Scholar
• Tuzcu A, Yalaki S, Arikan S, et al. Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique. Pituitary. 2009;12:330–333.
   PubMed Web of Science ®Google Scholar
• Serri O, Li L, Mamputu JC, et al. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf). 2006;64:366–370.
   PubMed Web of Science ®Google Scholar
• Tuzcu A, Bahceci M, Dursun M, et al. Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest. 2003;26:341–346.
   PubMed Web of Science ®Google Scholar
• Yavuz D, Deyneli O, Akpinar I, et al. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol. 2003;149:187–193.
   PubMed Web of Science ®Google Scholar
• Biller BMK, Colao A, Petersenn S, et al. Prolactinomas, Cushing’s disease and acromegaly: debating the role of medical therapy for secretoty pituitary adenomas. BMC Endocr Disord. 2010;10:10.
   PubMed Web of Science ®Google Scholar
• Gillam MP, Molitch ME, Lombardi G, et al. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485–534.
   PubMed Web of Science ®Google Scholar
• Cincotta A, Schiller B, Meier A. Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance and impaired glucose tolerance in the Syrian hamster, Mesoricetusauratus. Metabolism. 1991;40:639–644.
   PubMed Web of Science ®Google Scholar
• Cincotta A, MacEachern T, Meier A. Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol. 1993;264:E285–E293.
   PubMed Web of Science ®Google Scholar
• Cincotta A, Meier A. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care. 1996;19:667–670.
   PubMedGoogle Scholar
• Kamath V, Jones C, Yip J, et al. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese non diabetic hyperinsulinemic women. Diabetes Care. 1997;20:1697–1701.
   PubMed Web of Science ®Google Scholar
• Cincotta AH, Meier AH, Taylor E, et al. Bromocriptine (Ergoset) reduces body fat, hyperinsulinemia, and glucose intolerance in obese subjects (Abstract). Diabetes. 1995;44(Suppl. 1):168A.
   Google Scholar
• Galluzzi F, Salti R, Stagi S, et al. Reversible weight gain and prolactin levels—long-term follow-up in childhood. J Pediatr Endocrinol Metab. 2005;18:921–924.
   PubMed Web of Science ®Google Scholar
• Kamath V, Jones CN, Yip JC, et al. Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese non diabetic hyperinsulinemic women. Diabetes Care. 1997;20:1697–1701.
   PubMed Web of Science ®Google Scholar
• Pijl H, Ohashi S, Matsuda M, et al. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23(8):1154–1161.
   PubMed Web of Science ®Google Scholar
• Holt RI, Barnett AH, Bailey CJ. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab. 2010;12:1048–1057.
   PubMed Web of Science ®Google Scholar
• Bahar A, Kashi Z, Daneshpour E, et al. Effects of cabergoline on blood glucose levels in type 2 diabetic patients: a double-blind controlled clinical trial. Medicine (Baltimore). 2016;95(40):e4818.
   PubMed Web of Science ®Google Scholar
• Pala NA, Laway BA, Misgar RA, et al. Metabolic abnormalities in patients with prolactinoma: response to treatment with cabergoline. Diabetol Metab Syndr. 2015 Nov;14(7):99.
   Google Scholar
• Berinder K, Nystrom T, Hoybye C, et al. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary. 2011;14:199–207.
   PubMed Web of Science ®Google Scholar
• Naliato EC, Violante AH, Gaccione M, et al. Body fat in men with prolactinomas. J Endocrinol Invest. 2008;31(11):985–990.
   PubMed Web of Science ®Google Scholar
• Naliato EC, Violante AH, Caldas D, et al. Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin Endocrinol (Oxf). 2007;67(6):845–852.
   PubMed Web of Science ®Google Scholar
• dos Santos Silva CM, Barbosa FR, Lima GA, et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity (Silver Spring). 2011;19:800–805.
   PubMed Web of Science ®Google Scholar
• Korner J, Lo J, Freda PU, et al. Treatment with cabergoline is associated with weight loss in patients with hyperprolactinemia. Obes Res. 2003;11:311–312.
   PubMedGoogle Scholar
• Ciresi A, Amato MC, Guarnotta V, et al. Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin Endocrinol (Oxf). 2013 Dec;79(6):845–852.
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Granieri L, Galdiero M, et al. Effect of cabergoline on metabolism in prolactinomas. Neuroendocrinology. 2013;98(4):299–310.
   PubMed Web of Science ®Google Scholar
• Bhansali A, Walia R, Dutta P, et al. Efficacy of cabergoline on rapid escalation of dose in men with macroprolactinomas. Indian J Med Res. 2010;131:530–535.
   PubMed Web of Science ®Google Scholar
• De Rosa M, Ciccarelli A, Zarrilli S, et al. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. Clin Endocrinol (Oxf). 2006;64(3):307–313.
   PubMed Web of Science ®Google Scholar
• Colao A, Vitale G, Cappabianca P, et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab. 2004;89(4):1704–1711.
   PubMed Web of Science ®Google Scholar
• Auriemma RS, Galdiero M, Vitale P, et al. Effect of chronic cabergoline treatment and testosterone replacement on metabolism in male patients with prolactinomas. Neuroendocrinology. 2015;101(1):66–81.
   PubMed Web of Science ®Google Scholar
• Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22(6):724–763.
   PubMed Web of Science ®Google Scholar
• Hsu B, Cumming RG, Naganathan V, et al. Associations between circulating reproductive hormones and SHBG and prevalent and incident metabolic syndrome in community-dwelling older men: the concord health and ageing in men project. J Clin Endocrinol Metab. 2014;99(12):E2686–91.
   PubMed Web of Science ®Google Scholar
• EMAS Group, Camacho EM, Huhtaniemi IT, O’Neill TW, et al. Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol. 2013;168(3):445–455.
   PubMed Web of Science ®Google Scholar
• Medic-Stojanoska M, Icin T, Pletikosic I, et al. Risk factors for accelerated atherosclerosis in young women with hyperprolactinemia. Med Hypotheses. 2015 Apr;84(4):321–326.
   PubMed Web of Science ®Google Scholar
• Ben-Jonathan N, Hugo E. Prolactin (PRL) in adipose tissue: regulation and functions. Adv Exp Med Biol. 2015;846:1–35.
   PubMed Web of Science ®Google Scholar
• Pelkonen R, Salmi J, Lamberg BA. Interrelationship between TSH- and prolactin secretion in patients with prolactinoma and autoimmune thyroiditis. Acta Endocrinol (Copenh). 1982;100(2):184–188.
   PubMedGoogle Scholar
• Heshmati HM, Turpin G, De Gennes JL. Chronic hyperprolactinemia and plasma lipids in women. KlinWochenschr. 1987;65(11):516–519.
   PubMedGoogle Scholar
• Oravec S, Tomecková E, Oravec D, et al. Decreased apolipoprotein levels in women with hyperprolactinemia related to increased estradiol level: effect of hepatic lesion? Endocrinol Exp. 1985;19(4):312–316.
   PubMedGoogle Scholar
• Erem C, Kocak M, Nuhoglu I, et al. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin Endocrinol (Oxf). 2010;73(4):502–507.
   PubMed Web of Science ®Google Scholar
• McAveney KM, Gimble JM, Yu-Lee L. Prolactin receptor expression during adipocyte differentiation of bone marrow stroma. Endocrinology. 1996;137(12):5723–5726.
   PubMed Web of Science ®Google Scholar
• Symonds ME, Phillips ID, Anthony RV, et al. Prolactin receptor gene expression and foetal adipose tissue. J Neuroendocrinol. 1998;10(11):885–890.
   PubMed Web of Science ®Google Scholar
• Gualillo O, Lago F, García M, et al. Prolactin stimulates leptin secretion by rat white adipose tissue. Endocrinology. 1999;140(11):5149–5153.
   PubMed Web of Science ®Google Scholar
• Hugo ER, Borcherding DC, Gersin KS, et al. Prolactin release by adipose explants, primary adipocytes, and LS14 adipocytes. J Clin Endocrinol Metab. 2008;93(10):4006–4012.
   PubMed Web of Science ®Google Scholar
• Borcherding DC, Hugo ER, Idelman G, et al. Dopamine receptors in human adipocytes: expression and functions. PloS One. 2011;6(9):e25537.
   PubMed Web of Science ®Google Scholar
• AlkaMeSyStudy Group, Amato MC, Giordano C, Galia M, et al. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920–922.
   PubMed Web of Science ®Google Scholar
• Ciresi A, Amato MC, Pizzolanti G, et al. Visceral adiposity index is associated with insulin sensitivity and adipocytokine levels in newly diagnosed acromegalic patients. J ClinEndocrinolMetab. 2012;97(8):2907–2915.
   PubMed Web of Science ®Google Scholar
• Amato MC, Verghi M, Galluzzo A, et al. The oligomenorrhoic phenotypes of polycystic ovary syndrome are characterized by a high visceral adiposity index: a likely condition of cardiometabolic risk. Hum Reprod. 2011;26(6):1486–1494.
   PubMed Web of Science ®Google Scholar
• Schwetz V, Librizzi R, Trummer C, et al. Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas. Metab Brain Dis. 2017 Feb;32(1):155–161.
   PubMed Web of Science ®Google Scholar
• Liang Y, Lubkin M, Sheng H, et al. Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice. Biochim Biophys Acta. 1998;1405((1–3):1–13.
   PubMed Web of Science ®Google Scholar
• Contreras F, Foullioux C, Pacheco B, et al. Effect of drugs interacting with the dopaminergic receptors on glucose levels and insulin release in healthy and type 2 diabetic subjects. Am J Ther. 2008;15(4):397–402.
   PubMed Web of Science ®Google Scholar
• Balbach L, Wallaschofski H, Völzke H, et al. Serum prolactin concentrations as risk factor of metabolic syndrome or type 2 diabetes? BMC EndocrDisord. 2013;13:12.
   PubMed Web of Science ®Google Scholar
• Sorenson RL, Brelje TC, Roth C. Effects of steroid and lactogenic hormones on islets of Langerhans: a new hypothesis for the role of pregnancy steroids in the adaptation of islets to pregnancy. Endocrinology. 1993;133(5):2227–2234.
   PubMed Web of Science ®Google Scholar
• Brelje TC, Scharp DW, Lacy PE, et al. Effect of homologous placental lactogens, prolactins, and growth hormones on islet B-cell division and insulin secretion in rat, mouse, and human islets: implication for placental lactogen regulation of islet function during pregnancy. Endocrinology. 1993;132(2):879–887.
   PubMed Web of Science ®Google Scholar
• Petryk A, Fleenor D, Driscoll P, et al. Prolactin induction of insulin gene expression: the roles of glucose and glucose transporter-2. J Endocrinol. 2000;164(3):277–286.
   PubMed Web of Science ®Google Scholar
• Fleenor DE, Freemark M. Prolactin induction of insulin gene transcription: roles of glucose and signal transducer and activator of transcription 5. Endocrinology. 2001;142(7):2805–2810.
   PubMed Web of Science ®Google Scholar
• Kim SY, Sung YA, Ko KS, et al. Direct relationship between elevated free testosterone and insulin resistance in hyperprolactinemic women. Korean J Intern Med. 1993;8(1):8–14.
   PubMedGoogle Scholar
• Pelkonen R, Nikkilä EA, Grahne B. Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. ClinEndocrinol (Oxf). 1982;16(4):383–390.
   PubMed Web of Science ®Google Scholar
• Foss MC, Paula FJ, Paccola GM, et al. Peripheral glucose metabolism in human hyperprolactinaemia. Clin Endocrinol (Oxf). 1995;43(6):721–726.
   PubMed Web of Science ®Google Scholar
• Rubí B, Ljubicic S, Pournourmohammadi S, et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem. 2005;280(44):36824–36832.
   PubMed Web of Science ®Google Scholar
• Ericson LE, Håkanson R, Lundquist I. Accumulation of dopamine in mouse pancreatic B-cells following injection of L-DOPA. Localization to secretory granules and inhibition of insulin secretion. Diabetologia. 1977;13(2):117–124.
   PubMed Web of Science ®Google Scholar
• Zern RT, Bird JL, Feldman JM. Effect of increased pancreatic islet norepinephrine, dopamine and serotonin concentration on insulin secretion in the golden hamster. Diabetologia. 1980;18(4):341–346.
   PubMed Web of Science ®Google Scholar
• Rosati G, Maioli M, Aiello I, et al. Effects of long-term L-dopa therapy on carbohydrate metabolism in patients with Parkinson’s disease. Eur Neurol. 1976;14(3):229–239.
   PubMed Web of Science ®Google Scholar
• Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab. 2009;94(1):223–230.
   PubMed Web of Science ®Google Scholar
• Kok P, Roelfsema F, Frölich M, et al. Short-term treatment with bromocriptine improves impaired circadian growth hormone secretion in obese premenopausal women. JClin Endocrinol Metab. 2008;93(9):3455–3461.
   Google Scholar
• Vitale G, Brugts MP, Ogliari G, et al. Low circulating IGF-I bioactivity is associated with human longevity: findings in centenarians’ offspring. Aging (Albany NY). 2012;4(9):580–589.
   PubMedGoogle Scholar
• Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: A systematic review of studies published between 1931 and 1999. Obes Rev. 2000;1:113–119.
   PubMedGoogle Scholar
• Matsuzawa Y, Sugiyama S, Sugamura K, et al. Successful diet and exercise therapy as evaluated on self-assessment score significantly improves endothelial function in metabolic syndrome patients. Circ J. 2013;77(11):2807–2815.
   PubMed Web of Science ®Google Scholar
• Savino W. Prolactin: an immunomodulator in health and disease. Front Horm Res. 2017;48:69–75.
   PubMed Web of Science ®Google Scholar
• Watad A, Versini M, Jeandel PY, et al. Treating prolactinoma can prevent autoimmune diseases. Cell Immunol. 2015;294:84–86.
   PubMed Web of Science ®Google Scholar
• Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev. 2007;6:537–542.
   PubMed Web of Science ®Google Scholar
• Toffoli Ribeiro C, Louzada Junior P, De Sa MFS. Correlation between systemic lupus erythematosus activity and plasma levels of monomeric prolactin and macroprolactin. Endocr Metab Immune Disord Drug Targets. 2016;16(1):21–27.
   PubMed Web of Science ®Google Scholar
• Zhu X, Xu J, Li S, et al. Role of abnormal anterior pituitary hormonesgrowth hormone and prolactin in active systemic lupus erythematosus. Int J Clin Exp Med. 2015;8:19223–19231.
   PubMed Web of Science ®Google Scholar
• Legorreta-Haquet MV, Chavez-Rueda K, Chavez-Sanchez L, et al. Function of Treg cells decreased in patients with systemic lupus erythematosus due to the effect of prolactin. Medicine (Baltimore). 2016;95:e2384.
   PubMed Web of Science ®Google Scholar
• Peeva E, Venkatesh J, Michael D, et al. Prolactin as a modulator of B cell function: implications for SLE. Biomed Pharmacother. 2004;58:310.
   PubMed Web of Science ®Google Scholar
• Jara LJ, Medina G, Saavedra MA, et al. Prolactin and autoimmunity. Clin Rev Allergy Immunol. 2011;40:50–59.
   PubMed Web of Science ®Google Scholar
• Sayki Arslan M, Sahin M, Topaloglu O, et al. Hyperprolactinaemia associated with increased thyroid volume and autoimmune thyroiditis in patients with prolactinoma. Clin Endocrinol (Oxf). 2013;79:882–886.
   PubMed Web of Science ®Google Scholar
• Elenkova A, Petrossians P, Zacharieva S, et al. High prevalence of autoimmune thyroid diseases in patients with prolactinomas: a cross-sectional retrospective study in a single tertiary referral centre. Ann Endocrinol (Paris). 2016;77:37–42.
   PubMed Web of Science ®Google Scholar
• Watad A, Cohen AD, Comaneshter D, et al. Hyperthyroidism association with SLE, lessons from real-life data – a case-control study. Autoimmunity. 2016;49:17–20.
   PubMed Web of Science ®Google Scholar
• Cejkova P, Fojtikova M. Cerna M: immunomodulatory role of prolactin in diabetes development. Autoimmun Rev. 2009;9:23–27.
   PubMed Web of Science ®Google Scholar
• Etemadifar M, Najafi MA, Najafi MR, et al. Multiple sclerosis and hyperprolactinemia: a case-control study. Acta Neurol Belg. 2015;115:253–257.
   PubMed Web of Science ®Google Scholar
• Yousefi M, Mozafari N, Hosseini MS, et al. Younespour S: evaluating serum prolactin and serum dehydroepiandrosterone sulfate levels in patients with pemphigus. Int J Dermatol. 2016;55:e332–e337.
   PubMed Web of Science ®Google Scholar
• Walker SE. Treatment of systemic lupus erythematosus with bromocriptine. Lupus. 2001;10:197–202.
   PubMed Web of Science ®Google Scholar
• Blank M, Krause I, Buskila D, et al. Bromocriptine immunomodulation of experimental SLE and primary antiphospholipid syndrome via induction of nonspecific T suppressor cells. Cell Immunol. 1995;162:114–122.
   PubMed Web of Science ®Google Scholar
• McMurray RW, Weidensaul D, Allen SH, et al. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol. 1995;22:2084–2091.
   PubMed Web of Science ®Google Scholar
• Qian Q, Liuqin L, Hao L, et al. The effects of bromocriptine on preventing postpartum flare in systemic lupus erythematosus patients from South China. J Immunol Res. 2015;2015:316965.
   PubMedGoogle Scholar
• Yang XY, Liang LQ, Xu HS, et al. Efficacy of oral bromocriptine in protecting the postpartum systemic lupus erythematosus patients from disease relapse. Zhonghua Nei Ke Za Zhi. 2003;42:621–624.
   PubMedGoogle Scholar